Vasiliki Daikopoulou

Ms. Vasiliki Daikopoulou


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2021 in Molecules
Verified
Journal Article
Open access
PDF file
VDVasiliki Daikopoulou
Vasiliki Daikopoulou
PAPanagiotis Apostolou
Panagiotis Apostolou
SMSofia Mourati
Sofia Mourati
IVIoanna Vlachou
Ioanna Vlachou
MGMaria Gougousi
Maria Gougousi
IPIoannis Papasotiriou
Ioannis Papasotiriou
Despite the fact that COVID-19 vaccines are already available on the market, there have not been any effective FDA-approved drugs to treat this disease. There are several already known drugs that through drug repositioning have shown an inhibitory activity against SARS-CoV-2 RNA-dependent RNA polymerase. These drugs are included in the family of nucleoside analogues. In our efforts, we synthesized a group of new nucleoside analogues, which are modified at the sugar moiety that is replaced by a quinazoline entity. Different nucleobase derivatives are used in order to increase the inhibition. Five new nucleoside analogues were evaluated with in vitro assays for targeting polymerase of SARS-CoV-2.

1 December 2019 in Molecules
Verified
Journal Article
Open access
PDF file
PPPanagiotis Parsonidis
Panagiotis Parsonidis
MSMAHAMMAD SHAIK
MAHAMMAD SHAIK
ASAthanasia P. Serafeim
Athanasia P. Serafeim
IVIoanna Vlachou
Ioanna Vlachou
VDVasiliki Daikopoulou
Vasiliki Daikopoulou
IPIoannis Papasotiriou
Ioannis Papasotiriou
Despite the fact that there are several anticancer drugs available, cancer has evolved using different pathways inside the cell. The protein tyrosine phosphatases pathway is responsible for monitoring cell proliferation, diversity, migration, and metabolism. More specifically, the SHP2 protein, which is a member of the PTPs family, is closely related to cancer. In our efforts, with the aid of a structure-based drug design, we optimized the known inhibitor SHP099 by introducing 1-(methylsulfonyl)-4-prolylpiperazine as a linker. We designed and synthesized three pyrazine-based small molecules. We started with prolines as cyclic amines, confirming that our structures had the same interactions with those already existing in the literature, and, here, we report one new hydrogen bond. These studies concluded in the discovery of methyl (6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl)prolylprolinate hydrochloride as one of the final compounds which is an active and acceptable cytotoxic agent.